TY - JOUR
T1 - The Preventable Productivity Burden of Kidney Disease in Australia
AU - Savira, Feby
AU - Ademi, Zanfina
AU - Wang, Bing
AU - Kompa, Andrew
AU - Owen, Alice
AU - Liew, Danny
AU - Zomer, Ella
N1 - Funding Information:
D. Liew reports receiving honoraria or study grants from Abbvie, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Pfizer, Sanofi, and Shire. A.J. Owen is an editorial board member for Nutrients. F. Savira is supported by a Monash International Postgraduate Research Scholarship, Monash Graduate Scholarship, and Monash Postgraduate Publication Award. E. Zomer reports receiving study grants from Amgen, AstraZeneca, Pfizer, and Shire. This research funding is unrelated to this study and the funding organizations have no role in the design or interpretation of this study. D. Liew reports Consultancy Agreements with Abbvie, Astellas, AstraZeneca, Bristol-Myers Squibb, Edwards Lifesciences, Novartis, Pfizer, Sanofi, Shire; Research Funding from Abbvie, Astellas, AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi, Shire; Honoraria from Abbvie, Astellas, AstraZeneca, Bristol-Myers Squibb, Edwards Lifesciences, Novartis, Pfizer, Sanofi, and Shire. All remaining authors have nothing to disclose.
Publisher Copyright:
© 2021 by the American Society of Nephrology.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Background Kidney disease is associated with impaired work productivity. However, the collective effect of missedwork days, reduced output at work, and early withdrawal fromthe workforce is rarely considered in health-economic evaluations. Methods To determine the effect on work productivity of preventing incident cases of kidney disease, using the novel measure "productivity-adjusted life year"(PALY), we constructed a dynamic life table model for the Australian working-age population (aged 15-69 years) over 10 years (2020-2029), stratified by kidney-disease status. Input data, including productivity estimates, were sourced from the literature. We ascribed a financial value to the PALY metric in terms of gross domestic product (GDP) per equivalent full-time worker and assessed the total number of years lived, total PALYs, and broader economic costs (GDP per PALY). We repeated the model simulation, assuming a reduced kidney-disease incidence; the differences reflected the effects of preventing new kidney-disease cases. Outcomes were discounted by 5% annually. Results Our projections indicate that, from 2020 to 2029, the estimated number of new kidney-disease cases will exceed 161,000. Preventing 10% of new cases of kidney disease during this period would result in.300 premature deaths averted and approximately 550 years of life and 7600 PALYs saved-equivalent to a savings of US$1.1 billion in GDP or US$67,000 per new case avoided. Conclusions Pursuing a relatively modest target for preventing kidney disease in Australia may prolong years of life lived and increase productive life years, resulting in substantial economic benefit. Our findings highlight the need for investment in preventive measures to reduce future cases of kidney disease.
AB - Background Kidney disease is associated with impaired work productivity. However, the collective effect of missedwork days, reduced output at work, and early withdrawal fromthe workforce is rarely considered in health-economic evaluations. Methods To determine the effect on work productivity of preventing incident cases of kidney disease, using the novel measure "productivity-adjusted life year"(PALY), we constructed a dynamic life table model for the Australian working-age population (aged 15-69 years) over 10 years (2020-2029), stratified by kidney-disease status. Input data, including productivity estimates, were sourced from the literature. We ascribed a financial value to the PALY metric in terms of gross domestic product (GDP) per equivalent full-time worker and assessed the total number of years lived, total PALYs, and broader economic costs (GDP per PALY). We repeated the model simulation, assuming a reduced kidney-disease incidence; the differences reflected the effects of preventing new kidney-disease cases. Outcomes were discounted by 5% annually. Results Our projections indicate that, from 2020 to 2029, the estimated number of new kidney-disease cases will exceed 161,000. Preventing 10% of new cases of kidney disease during this period would result in.300 premature deaths averted and approximately 550 years of life and 7600 PALYs saved-equivalent to a savings of US$1.1 billion in GDP or US$67,000 per new case avoided. Conclusions Pursuing a relatively modest target for preventing kidney disease in Australia may prolong years of life lived and increase productive life years, resulting in substantial economic benefit. Our findings highlight the need for investment in preventive measures to reduce future cases of kidney disease.
UR - http://www.scopus.com/inward/record.url?scp=85111290348&partnerID=8YFLogxK
U2 - 10.1681/ASN.2020081148
DO - 10.1681/ASN.2020081148
M3 - Article
C2 - 33687979
AN - SCOPUS:85111290348
SN - 1046-6673
VL - 32
SP - 938
EP - 949
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 4
ER -